Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548–1565. doi: 10.1158/2159-8290.CD-18-0804
   PubMed Web of Science ®Google Scholar
• Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–416. doi: 10.1038/ng.3520
   PubMed Web of Science ®Google Scholar
• de Reyniès A, Jaurand M-C, Renier A, et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:1323–1334.
   PubMed Web of Science ®Google Scholar
• Blum Y, Meiller C, Quetel L, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 2019;10(1):1333. doi: 10.1038/s41467-019-09307-6
   PubMedGoogle Scholar
• Mangiante L, Alcala N, Sexton-Oates A, et al. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Nat Genet. 2023;55(4):607–618. doi: 10.1038/s41588-023-01321-1
   PubMed Web of Science ®Google Scholar
• Quetel L, Meiller C, Assié J-B, et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol. 2020;14(6):1207–1223. doi: 10.1002/1878-0261.12651
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet Lond Engl. 2016;387:1405–1414. doi: 10.1016/S0140-6736(15)01238-6
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Am Soc Clin Oncol. 2003;21(14):2636–2644. doi: 10.1200/JCO.2003.11.136
   PubMed Web of Science ®Google Scholar
• Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol. 2016;52:9–18. doi: 10.1016/j.humpath.2016.01.010
   PubMed Web of Science ®Google Scholar
• Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386. doi: 10.1016/S0140-6736(20)32714-8
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239–253. doi: 10.1016/S1470-2045(18)30765-4
   PubMed Web of Science ®Google Scholar
• Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530–1540. doi: 10.1016/S1470-2045(21)00471-X
   PubMed Web of Science ®Google Scholar
• Assié J-B, Crépin F, Grolleau E, et al. Immune-checkpoint inhibitors for malignant pleural mesothelioma: a French, multicenter, retrospective real-world study. Cancers. 2022;14(6):1498. doi: 10.3390/cancers14061498
   PubMed Web of Science ®Google Scholar
• Kucharczuk JC, Randazzo B, Chang MY, et al. Use of a “replication-restricted” herpes virus to treat experimental human malignant mesothelioma. Cancer Res. 1997 Feb 1;57(3):466–471
   PubMed Web of Science ®Google Scholar
• Sterman DH, Alley E, Stevenson JP, et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNα combined with chemotherapy. Clin Cancer Res. 2016;22(15):3791–3800. doi: 10.1158/1078-0432.CCR-15-2133
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Haas AR, Metzger S, et al. Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. Mol Ther. 2018;26(5):1198–1205. doi: 10.1016/j.ymthe.2018.02.015
   PubMed Web of Science ®Google Scholar
• Ponce S, Cedres S, Ricordel C, et al. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. J Immunother Cancer. 2023;11(9): e007552. doi: 10.1136/jitc-2023-007552
   PubMed Web of Science ®Google Scholar
• Danson SJ, Conner J, Edwards JG, et al. Oncolytic herpesvirus therapy for mesothelioma - a phase I/IIa trial of intrapleural administration of HSV1716. Lung Cancer (Amst Neth). 2020;150:145–151. doi: 10.1016/j.lungcan.2020.10.007
   PubMed Web of Science ®Google Scholar
• Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11(17):2389–2401. doi: 10.1089/104303400750038499
   PubMed Web of Science ®Google Scholar
• Ltd T. A phase 3, open-label, randomized, parallel group study to evaluate the efficacy and safety of intrapleural administration of adenovirus-delivered interferon alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with malignant pleural mesothelioma. clinicaltrials .gov. Report No: NCT03710876; 2021 [cited 2022 Sep 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03710876.
   Google Scholar
• Kuryk L, Haavisto E, Garofalo M, et al. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. Int J Cancer. 2016;139(8):1883–1893. doi: 10.1002/ijc.30228
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 [cited 2023 Mar 23];6(261). Available fromhttps://www.science.org/doi/10.1126/scitranslmed.3010162. doi: 10.1126/scitranslmed.3010162
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti–PD-1 agent Pembrolizumab. Cancer Discov. 2021;11(11):2748–2763. doi: 10.1158/2159-8290.CD-21-0407
   PubMed Web of Science ®Google Scholar
• Ghosn M, Cheema W, Zhu A. Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. Lung Cancer. 2022;165:1–9. doi: 10.1016/j.lungcan.2022.01.003
   PubMed Web of Science ®Google Scholar
• Hiltbrunner S, Britschgi C, Schuberth P, et al. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Ann Oncol. 2021;32(1):120–121. doi: 10.1016/j.annonc.2020.10.474
   PubMed Web of Science ®Google Scholar
• Weidemann S, Gagelmann P, Gorbokon N, et al. Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors. Biomedicines. 2021;9(4):397. doi: 10.3390/biomedicines9040397
   PubMed Web of Science ®Google Scholar
• Chintala NK, Restle D, Quach H, et al. CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. Lung Cancer. 2021;157:48–59. doi: 10.1016/j.lungcan.2021.05.004
   PubMed Web of Science ®Google Scholar
• Jacob M, Chang L, Puré E. Fibroblast activation protein in remodeling tissues. Curr Mol Med. 2012;12(10):1220–1243. doi: 10.2174/156652412803833607
   PubMed Web of Science ®Google Scholar
• Schuberth PC, Hagedorn C, Jensen SM, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013;11(1):187. doi: 10.1186/1479-5876-11-187
   PubMed Web of Science ®Google Scholar
• Szlosarek PW, Steele JP, Nolan L, et al. Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1–deficient malignant pleural mesothelioma: a randomized clinical trial. JAMA Oncol. 2017;3(1):58–66. doi: 10.1001/jamaoncol.2016.3049
   PubMed Web of Science ®Google Scholar
• Kindler HL, Burris HA, Sandler AB, et al. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs. 2009;27(1):75–81. doi: 10.1007/s10637-008-9160-1
   PubMed Web of Science ®Google Scholar
• Fennell DA, King A, Mohammed S, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021;9(6):593–600. doi: 10.1016/S2213-2600(20)30390-8
   PubMed Web of Science ®Google Scholar
• Zauderer MG, Szlosarek PW, Le Moulec S, et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022;23(6):758–767. doi: 10.1016/S1470-2045(22)00277-7
   PubMed Web of Science ®Google Scholar
• Fennell DA, King A, Mohammed S, et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022;23(3):374–381. doi: 10.1016/S1470-2045(22)00062-6
   PubMed Web of Science ®Google Scholar
• Fennell DA, Baas P, Taylor P, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with Merlin-stratified pleural mesothelioma: COMMAND—A Double-blind, randomized, phase II study. J Clin Oncol. 2019;37(10):790–798. doi: 10.1200/JCO.2018.79.0543
   PubMed Web of Science ®Google Scholar
• Papa S, Popat S, Shah R, et al. Phase 2 study of Sorafenib in malignant mesothelioma Previously treated with platinum-containing chemotherapy. J Thorac Oncol. 2013;8(6):783–787. doi: 10.1097/JTO.0b013e31828c2b26
   PubMed Web of Science ®Google Scholar
• Szlosarek PW, Klabatsa A, Pallaska A, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(23):7126–7131. doi: 10.1158/1078-0432.CCR-06-1101
   PubMed Web of Science ®Google Scholar
• Szlosarek PW, Baas P, Ceresoli GL, et al. ATOMIC-Meso: a randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma. J Clin Oncol. 2017;35(15_suppl):TPS8582–TPS8582. doi: 10.1200/JCO.2017.35.15_suppl.TPS8582
   Google Scholar
• Scoumanne A, Zhang J, Chen X. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res. 2009;37(15):4965–4976. doi: 10.1093/nar/gkp516
   PubMed Web of Science ®Google Scholar
• Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214–1218. doi: 10.1126/science.aad5214
   PubMed Web of Science ®Google Scholar
• Ismail IH, Davidson R, Gagné J-P, et al. Germline mutations in BAP1 impair its function in DNA Double-Strand Break repair. Cancer Res. 2014;74(16):4282–4294. doi: 10.1158/0008-5472.CAN-13-3109
   PubMed Web of Science ®Google Scholar
• Busacca S, Sheaff M, Arthur K, et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol. 2012;227(2):200–208. doi: 10.1002/path.3979
   PubMed Web of Science ®Google Scholar
• LaFave LM, Béguelin W, Koche R, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21(11):1344–1349. doi: 10.1038/nm.3947
   PubMed Web of Science ®Google Scholar
• Schoumacher M, Le Corre S, Houy A, et al. Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status. Nat Med. 2016;22(6):577–578. doi: 10.1038/nm.4098
   PubMed Web of Science ®Google Scholar
• Pandey GK, Landman N, Neikes HK, et al. Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Cell Rep Med. 2023;4(2):100915. doi: 10.1016/j.xcrm.2022.100915
   PubMedGoogle Scholar
• Paternot S, Raspé E, Meiller C, et al. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Mol Oncol. 2022. doi:10.1002/1878-0261.13351
   PubMed Web of Science ®Google Scholar
• Shapiro IM, Kolev VN, Vidal CM, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6(237):237ra68. doi: 10.1126/scitranslmed.3008639
   PubMed Web of Science ®Google Scholar
• Sato T, Sekido Y. NF2/Merlin inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci. 2018;19(4):988. doi: 10.3390/ijms19040988
   PubMed Web of Science ®Google Scholar
• Calvet L, Dos-Santos O, Spanakis E, et al. YAP1 is essential for malignant mesothelioma tumor maintenance. BMC Cancer. 2022;22(1):639. doi: 10.1186/s12885-022-09686-y
   PubMed Web of Science ®Google Scholar
• Zagiel B, Melnyk P, Cotelle P. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present). Expert Opin Ther Pat. 2022;32(8):899–912. doi: 10.1080/13543776.2022.2096436
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523. doi: 10.7554/eLife.02523
   PubMed Web of Science ®Google Scholar
• Wu J, Minikes AM, Gao M, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling. Nature. 2019;572(7769):402–406. doi: 10.1038/s41586-019-1426-6
   PubMed Web of Science ®Google Scholar
• Krug LM, Dao T, Brown AB, et al. WT1 PEPTIDE VACCINATIONS INDUCE CD4 and CD8 T CELL IMMUNE RESPONSES in PATIENTS with MESOTHELIOMA and NON-SMALL CELL LUNG CANCER. Cancer Immunol Immunother CII. 2010;59(10):1467–1479. doi: 10.1007/s00262-010-0871-8
   PubMed Web of Science ®Google Scholar
• Hassan R, Alley E, Kindler H, et al. Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(19):5787–5798. doi: 10.1158/1078-0432.CCR-19-0070
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181(12):1383–1390. doi: 10.1164/rccm.200909-1465OC
   PubMed Web of Science ®Google Scholar
• Cornelissen R, Hegmans JPJJ, Maat APWM, et al. Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma. Am J Respir Crit Care Med. 2016;193(9):1023–1031. doi: 10.1164/rccm.201508-1573OC
   PubMed Web of Science ®Google Scholar
• Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric anti-mesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:5927–5936. doi: 10.1158/1078-0432.CCR-14-0804
   PubMed Web of Science ®Google Scholar
• Kindler HL, Novello S, Bearz A, et al. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022;23(4):540–552. doi: 10.1016/S1470-2045(22)00061-4
   PubMed Web of Science ®Google Scholar
• Meirson T, Pentimalli F, Cerza F, et al. Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open. 2022;5(3):e221490. doi: 10.1001/jamanetworkopen.2022.1490
   PubMed Web of Science ®Google Scholar
• Correale P, Pentimalli F, Nardone V, et al. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? Lancet Oncol. 2022;23(1):e13. doi: 10.1016/S1470-2045(21)00702-6
   PubMed Web of Science ®Google Scholar
• Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European thoracic oncology platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(12):1734–1745. doi: 10.1016/j.annonc.2020.09.009
   PubMed Web of Science ®Google Scholar
• Forde PM, Sun Z, Anagnostou V, et al. PrE0505: phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study. J Clin Oncol. 2020;38(15_suppl):9003–9003. doi: 10.1200/JCO.2020.38.15_suppl.9003
   Web of Science ®Google Scholar
• Haakensen VD, Nowak AK, Ellingsen EB, et al. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. J Transl Med. 2021;19(1):232. doi: 10.1186/s12967-021-02905-3
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Minor D, et al. Talimogene Laherparepvec in combination with ipilimumab in Previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619–2626. doi: 10.1200/JCO.2016.67.1529
   PubMed Web of Science ®Google Scholar
• Muller S, Victoria Lai W, Adusumilli PS, et al. V-domain ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod Pathol. 2020;33(2):303–311. doi: 10.1038/s41379-019-0364-z
   PubMed Web of Science ®Google Scholar
• Wirawan A, Tajima K, Takahashi F, et al. A novel therapeutic strategy targeting the mesenchymal phenotype of malignant pleural mesothelioma by suppressing LSD1. Mol Cancer Res. 2022;20(1):127–138. doi: 10.1158/1541-7786.MCR-21-0230
   PubMed Web of Science ®Google Scholar
• Chan M, Wu L, Yun Z, et al. Blocking the GITR-GITRL pathway to overcome resistance to therapy in sarcomatoid malignant pleural mesothelioma. Commun Biol. 2021;4(1):914. doi: 10.1038/s42003-021-02430-5
   PubMed Web of Science ®Google Scholar
• Dell’anno I, Melani A, Martin SA, et al. A drug Screening Revealed Novel Potential Agents against malignant pleural mesothelioma. Cancers. 2022;14(10):2527. doi: 10.3390/cancers14102527
   PubMed Web of Science ®Google Scholar
• Anobile DP, Bironzo P, Picca F, et al. Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers. 2021;13(10):2332. doi: 10.3390/cancers13102332
   PubMed Web of Science ®Google Scholar
• Setargew YFI, Wyllie K, Grant RD, et al. Targeting lysyl oxidase family meditated matrix cross-linking as an anti-stromal therapy in solid tumours. Cancers. 2021;13(3):491. doi: 10.3390/cancers13030491
   PubMed Web of Science ®Google Scholar
• Blanquart C, Jaurand M-C, Jean D. The biology of malignant mesothelioma and the relevance of preclinical models. Front Oncol. 2020;10:388. doi: 10.3389/fonc.2020.00388
   PubMed Web of Science ®Google Scholar
• Stern E, Caruso S, Meiller C, et al. Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics. Front Immunol. 2023;13:1026185. doi: 10.3389/fimmu.2022.1026185
   PubMedGoogle Scholar
• van Renterghem AWJ, van de Haar J, Voest EE. Functional precision oncology using patient-derived assays: bridging genotype and phenotype. Nat Rev Clin Oncol. 2023;20:305–317. doi: 10.1038/s41571-023-00745-2
   PubMed Web of Science ®Google Scholar
• Cova E, Pandolfi L, Colombo M, et al. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study. Int J Nanomedicine. 2019;14:773–785.
   PubMed Web of Science ®Google Scholar